Alpha 2.0
Login Register
» Authors » Wim Noel

Wim Noel

Explore the profile of Wim Noel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 866
Followers 0
Related Specialties
Rheumatology
Allergy & Immunology
Hematology
Top 10 Co-Authors
Elke Theander
Patrick De Baetselier
Laure Gossec
Geert Raes
Paul Bergmans
Josef S Smolen
Alain Beschin
Stefan Siebert
Lea Brys
Elisa Gremese
Published In
Ann Rheum Dis
J Immunol
J Leukoc Biol
Rheumatol Adv Pract
Rheumatology (Oxford)
Affiliations
Soon will be listed here.
Recent Articles
1.
Patient Profiles in Randomized Controlled Trials Versus a Real-World Study in Psoriatic Arthritis: Scoping Review and Metaanalysis
Alle G, Lopez-Medina C, Siebert S, Lavie F, Noel W, Smolen J, et al.
J Rheumatol . 2024 Nov; 52(2):138-144. PMID: 39547694
Objective: Patients with psoriatic arthritis (PsA) in randomized controlled trials (RCTs) may not reflect patients with PsA in clinical practice. Our objective was to perform a metaanalysis comparing the characteristics...
2.
Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study
Cherif H, Cai Q, Crivera C, Leon A, Rahman I, Leval A, et al.
Eur J Haematol . 2024 Oct; 114(1):129-138. PMID: 39382375
Objectives: Warm autoimmune hemolytic anemia (wAIHA) is a rare autoantibody-mediated disorder, and first-line treatment primarily relies on corticosteroids. This study assessed overall survival (OS) and treatment patterns of wAIHA in...
3.
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials
Thilakarathne P, Schubert A, Peterson S, Noel W, Patel B, Hassan F
Rheumatol Ther . 2024 Feb; 11(2):457-474. PMID: 38416392
Introduction: Two biologic therapies for psoriatic arthritis (PsA), guselkumab and ustekinumab, have demonstrated superior efficacy versus placebo in clinical trials. However, no head-to-head studies have been conducted comparing these two...
4.
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study
Gossec L, Siebert S, Bergmans P, De Vlam K, Gremese E, Joven-Ibanez B, et al.
Arthritis Res Ther . 2023 Jun; 25(1):109. PMID: 37353788
Background: To evaluate the real-world effect of the IL-12/23 inhibitor ustekinumab or of a tumour necrosis factor inhibitor (TNFi) on patient-reported outcomes (PRO) and their association with effectiveness endpoints in...
5.
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
Gossec L, Theander E, Chakravarty S, Bergmans P, Lavie F, Noel W, et al.
Arthritis Res Ther . 2023 Jun; 25(1):100. PMID: 37296456
Background: This post-hoc analysis of PsABio (NCT02627768) evaluated safety, effectiveness and treatment persistence in patients < 60 and ≥ 60 years of age receiving ustekinumab over 3 years. Methods: Measures...
6.
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
Richette P, Vis M, Ohrndorf S, Tillett W, Ramirez J, Neuhold M, et al.
RMD Open . 2023 Mar; 9(1). PMID: 37001920
Objectives: Psoriatic arthritis (PsA) phenotypes are typically defined by their clinical components, which may not reflect patients' overlapping symptoms. This post hoc analysis aimed to identify hypothesis-free PsA phenotype clusters...
7.
Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data
van Kuijk A, Nurmohamed M, Siebert S, Bergmans P, De Vlam K, Gremese E, et al.
Rheumatology (Oxford) . 2023 Feb; 62(10):3382-3390. PMID: 36810788
Objective: Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. Methods: PsABio is a non-interventional European study in patients with PsA starting a biological DMARD...
8.
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study
Gossec L, Siebert S, Bergmans P, De Vlam K, Gremese E, Joven-Ibanez B, et al.
Ann Rheum Dis . 2023 Jan; 82(4):496-506. PMID: 36600178
Objectives: To evaluate real-world persistence and effectiveness of the IL-12/23 inhibitor, ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. Methods: PsABio (NCT02627768), a prospective,...
9.
Persistence, effectiveness and safety of ustekinumab compared to TNF inhibitors in psoriatic arthritis within the Italian PsABio cohort
Gremese E, Ciccia F, Selmi C, Cuomo G, Foti R, Matucci-Cerinic M, et al.
Clin Exp Rheumatol . 2022 Oct; 41(3):735-743. PMID: 36226614
Objectives: To compare real-world persistence, effectiveness and tolerability of ustekinumab versus TNF inhibitors (TNFi) in psoriatic arthritis (PsA). Methods: One-year data from Italian subjects enrolled in the PsABio study (PsA...
10.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
Coates L, Ritchlin C, Gossec L, Helliwell P, Rahman P, Kollmeier A, et al.
Rheumatology (Oxford) . 2022 Jun; 62(2):606-616. PMID: 35766811
Objectives: To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing composite indices. Methods: Data were pooled from the phase 3 DISCOVER-1 (n = 381) and DISCOVER-2...